

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT3534590

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
WEI CHEN	09/14/2015
LONGCHENG WANG	09/09/2015
ZHAOZHONG J. JIA	09/11/2015
GORDANA BABIC ATALLAH	09/11/2015
DAVID J. LOURY	09/17/2015
RECEIVING PARTY DATA	
Name:	PHARMACYCLICS L.L.C.
Street Address:	995 EAST ARQUES AVENUE
City:	SUNNYVALE
State/Country:	CALIFORNIA
Postal Code:	94085
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	14790978
CORRESPONDENCE DATA	
Fax Number:	(201)587-0715
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	2014875800
Email:	info@kjiplaw.com
Correspondent Name:	KLAUBER & JACKSON LLC
Address Line 1:	25 EAST SPRING VALLEY AVENUE
Address Line 2:	SUITE 160
Address Line 4:	MAYWOOD, NEW JERSEY 07607
ATTORNEY DOCKET NUMBER:	3446-1-001N
NAME OF SUBMITTER:	DAVID A. JACKSON
SIGNATURE:	/David A. Jackson/
DATE SIGNED:	09/21/2015
Total Attachments: 4	

source=3446_1_001N_executed_Assignment_Inventors_PCYC#page1.tif

source=3446_1_001N_executed_Assignment_Inventors_PCYC#page2.tif

source=3446_1_001N_executed_Assignment_Inventors_PCYC#page3.tif

source=3446_1_001N_executed_Assignment_Inventors_PCYC#page4.tif

PATENT ASSIGNMENT

Docket Numbers 00501US, 00501WO AND 00501WO2 (3446-1-001N, 3446-1-001PCT, and 3446-1-001PCT2)

WHEREAS, the undersigned:

- | | | |
|---|---|---|
| 1. CHEN, Wei
Pharmacyclics LLC
1668 Walden Court
Fremont, CA 94539 | 2. WANG, Longcheng
Pharmacyclics LLC
4294 Wilkie Way, Apt. L
Palo Alto, CA 94306 | 3. LOURY, David J.
Pharmacyclics LLC
7130 Galli Drive
San Jose, CA 95129 |
| 4. JIA, Zhaozhong J.
Pharmacyclics LLC
3416 Leafwood Court
San Mateo, California 94403 | 5. ATALLAH, Gordana Babic
Pharmacyclics LLC
4493 Deep Creek Road
Fremont, CA 94555 | |

(hereinafter "Inventor(s)), have invented certain new and useful improvements in

INHIBITORS OF BRUTON'S TYROSINE KINASE

for which a United States patent application is executed on even date herewith;

for which application serial numbers 14/790,978, PCT/US2015/38937 AND PCT/US2015/38986 were filed on July 2, 2015 in the United States Patent and Trademark Office; (hereinafter, "Application(s)"). The term "Application(s)" also includes all patent applications that share or claim priority to or from the above application(s).

WHEREAS, **Pharmacyclics LLC**, having a place of business at **995 East Arques Avenue, Sunnyvale, CA 94085**, (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Application(s), and the inventions disclosed therein, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (hereinafter collectively referred to as "Inventions"), and in and to any and all patents, inventor's certificates and other forms of protection thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise (hereinafter "Patent(s)").

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:

1. Said Inventor(s) have sold, assigned, transferred, and conveyed and do hereby sell, assign, transfer and convey unto said Assignee, the inventor(s) entire right, title and interest (a) in and to said Inventions; (b) in and to said Applications, including the right to claim priority to and from said Application(s); (c) in and to each and every application that is a divisional, substitution, continuation, or continuation-in-part of any of said Application(s); (d) in and to said Patent(s) and each and every patent issuing or reissuing from any of the foregoing; (e) in and to each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing; (f) in and to each and every patent and application filed outside the United States and corresponding to any of the foregoing; and (g) in and to all claims for past, present and future infringement of the Patent(s), including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Patent(s).

2. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.

4. Said Inventor(s) hereby warrant, represent and covenant that said Inventor(s) have not entered and will not enter

PATENT ASSIGNMENT


Docket Numbers 00501US, 00501WO AND
00501WO2 (3446-1-001N, 3446-1-001PCT,
and 3446-1-001PCT2)


into any assignment, contract, or understanding in conflict herewith.

5. Said Inventor(s) hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.


6. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.


IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:

Date: Sep 14, 2015 Signature: 
Wei CHEN

Date: Sep 9, 2015 Signature: 
Longcheng WANG

Date: _____ Signature: _____
David J. LOURY

Date: 11 SEP 15 Signature: 
Zhaozhong J. JIA

Date: 11 Sep 15 Signature: 
Gordana Babic ATALLAH

PATENT ASSIGNMENT

Docket Numbers 00501US, 00501WO AND 00501WO2 (3446-1-001N, 3446-1-001PCT, and 3446-1-001PCT2)

WHEREAS, the undersigned:

- 1. CHEN, Wei
Pharmacyclics LLC
1668 Walden Court
Fremont, CA 94539
- 2. WANG, Longcheng
Pharmacyclics LLC
4294 Wilkie Way, Apt L
Palo Alto, CA 94306
- 3. LOURY, David J.
Pharmacyclics LLC
7130 Galli Drive
San Jose, CA 95129
- 4. JIA, Zhaozhong J.
Pharmacyclics LLC
3416 Leafwood Court
San Mateo, California 94403
- 5. ATALLAH, Gordana Babic
Pharmacyclics LLC
4493 Deep Creek Road
Fremont, CA 94555

(hereinafter "Inventor(s)), have invented certain new and useful improvements in

INHIBITORS OF BRUTON'S TYROSINE KINASE

for which a United States patent application is executed on even date herewith;
 for which application serial numbers 14/790,978, PCT/US2015/38937 AND PCT/US2015/38986 were filed on July 2, 2015 in the United States Patent and Trademark Office; (hereinafter, "Application(s)"). The term "Application(s)" also includes all patent applications that share or claim priority to or from the above application(s).

WHEREAS, Pharmacyclics LLC., having a place of business at 995 East Arques Avenue, Sunnyvale, CA 94085, (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Application(s), and the inventions disclosed therein, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (hereinafter collectively referred to as "Inventions"), and in and to any and all patents, inventor's certificates and other forms of protection thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise (hereinafter "Patent(s)").

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:

1. Said Inventor(s) have sold, assigned, transferred, and conveyed and do hereby sell, assign, transfer and convey unto said Assignee, the inventor(s) entire right, title and interest (a) in and to said Inventions; (b) in and to said Applications, including the right to claim priority to and from said Application(s); (c) in and to each and every application that is a divisional, substitution, continuation, or continuation-in-part of any of said Application(s); (d) in and to said Patent(s) and each and every patent issuing or reissuing from any of the foregoing; (e) in and to each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing; (f) in and to each and every patent and application filed outside the United States and corresponding to any of the foregoing; and (g) in and to all claims for past, present and future infringement of the Patent(s), including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Patent(s).

2. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.

4. Said Inventor(s) hereby warrant, represent and covenant that said Inventor(s) have not entered and will not enter

PATENT ASSIGNMENT

Docket Numbers 00501US, 00501WO AND
00501WO2 (3446-1-001N, 3446-1-001PCT,
and 3446-1-001PCT2)

into any assignment, contract, or understanding in conflict herewith.

5. Said Inventor(s) hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

6. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:

Date: _____ Signature: _____
Wei CHEN

Date: _____ Signature: _____
Longcheng WANG

Date: 17 September Signature: 
David L. LOURY

Date: _____ Signature: _____
Zhaozhong J. JIA

Date: _____ Signature: _____
Gordans Babic ATALLAH